Investors Urged to Join Kyverna Therapeutics Securities Fraud Lawsuit Before Deadline
Opportunity for Kyverna Therapeutics Investors to Lead Class Action
In a significant legal development, the global investor rights firm Rosen Law Firm has announced a compelling opportunity for those who purchased common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). The firm highlights that these investors may be able to join a class action lawsuit against the company related to alleged securities fraud, in the wake of its initial public offering (IPO) on February 8, 2024.
Important Deadline Approaching
Investors should take note of the looming deadline of February 7, 2025, to apply as lead plaintiffs in the case. Acting as a lead plaintiff allows investors to represent their peers and steer the direction of the litigation. Those who believe they are eligible to participate can visit Rosen Law's website or contact attorney Phillip Kim directly at 866-767-3653 for more information.
Allegations of Misrepresentation
The heart of the lawsuit centers around alleged misstatements and omissions in the registration statement and prospectus issued during Kyverna’s IPO. The complaint asserts that Kyverna misled investors regarding its lead product candidate, KYV-101. Although the company communicated patient
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.